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Background: To increase the chance of a live birth after in vitro fertilization (IVF) a controlled 
ovarian hormonal hyperstimulation (COH) is used to collect a certain number of oocytes for 
fertilization. COH is a potent hormonal treatment with a potential risk of serious adverse events. 
Aim: To assess the ovarian response, expressed as the number of oocytes retrieved for IVF that 
results in an optimal balance between efficacy and safety.  
Methods: Paper I: A randomized controlled trial (RCT), including 308 patients, comparing the 
performance of a dosage algorithm based on anti-Müllerian hormone (AMH) to one without 
AMH for prediction of the desired ovarian response, 5 to 12 oocytes. Paper II: A cohort study 
including 269 serum samples analyzed in a parallel setting investigating the correlation between 
the two AMH assays used in the RCT. Paper III: All fresh IVF cycles performed in Sweden 
2007-2013  (n=77,956) and their subsequent frozen embryo transfer (FET) cycles (n=36,270) 
performed 2007-2014 were included in a population based registry study. Four major outcomes 
were investigated in relation to the number of oocytes retrieved; live birth rate (LBR), 
cumulative LBR per fresh and all subsequent FET cycles, incidence of severe ovarian 
hyperstimulation syndrome (OHSS) and incidence of thromboembolic events. Paper IV: All 
singletons born after fresh IVF cycles in Sweden 2002-2015 (n=27,359) were included in a 
population based registry study. Five main perinatal outcomes (preterm birth [PTB], very 
preterm birth [VPTB], small for gestational age [SGA], major birth defects and peri/neonatal 
death) and two main obstetric outcomes (hypertensive disorders of pregnancy [HDP] and 
placenta praevia) were investigated in relation to the number of oocytes retrieved. Data was 
adjusted for maternal age, parity, smoking, BMI, cause of infertility, maternal educational level, 
maternal country of birth, treatment period, embryo stage, fertilization method (IVF/ICSI), 
OHSS and vanishing twin. 
Results: Paper I: There was no significant difference between the two algorithms regarding 
the primary outcome variable rate of patients with between 5 and 12 oocytes retrieved. Paper 
II: The correlation between the two assays was good, although there were considerable 
differences between the two assays depending on the actual AMH levels. Paper III: LBR after 
fresh cycles increased by the number of oocytes retrieved, although reaching a plateau at 11 
oocytes while cumulative LBR evened out at 20 oocytes retrieved. OHSS increased rapidly if 
more than 18 oocytes were retrieved. Thromboembolic events were rare and occurred mainly 
if more than 15 oocytes were retrieved. Paper IV: There was no significant association between 
the number of oocytes retrieved and any of the perinatal outcomes or HDP. There was however 
a significant association between the number of oocytes retrieved and placenta praevia. 
Conclusions: 1. Inclusion of AMH in dose decision did not result in a better prediction of 
ovarian response. 2. AMH assays have considerable and clinically important methodological 
problems 3. Ovarian stimulation up to 18 to 20 oocytes retrieved seems optimal from a 
cumulative live birth perspective, keeping severe adverse events at a reasonable level.  
4. Ovarian response was not associated with adverse perinatal outcome though a significant 
association was found with the risk of placenta praevia. 
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